Introduction
============

A major challenge in rare diseases is conducting clinical trials with sufficient power to inform best clinical practice when anticipated sample sizes are small. Historically, this has been a major barrier in rare paediatric autoimmune diseases. Bayesian methodology can be used to augment the sparse therapeutic data obtained from clinical trials in these circumstances.

Objectives
==========

We elicited expert prior opinion for a future Bayesian randomised controlled trial for a rare inflammatory paediatric disease, polyarteritis nodosa (MYPAN, Mycophenolate mofetil for polyarteritis nodosa).

Methods
=======

A Bayesian prior elicitation meeting was convened. Participating experts were drawn from across the EU and Turkey. Opinion was sought on the probability that a patient in the MYPAN trial treated with cyclophosphamide would achieve disease remission within 6-months, and on the relative efficacies of mycophenolate mofetil and cyclophosphamide. Expert opinion was combined with previously unseen data from a recently completed randomised controlled trial of mycophenolate mofetil versus cyclophosphamide in anti-neutrophil cytoplasmic antibody associated vasculitis.

Results
=======

A pan-European group of fifteen experts participated in the elicitation meeting. Consensus expert prior opinion was that the most likely rates of disease remission within 6 months on cyclophosphamide or mycophenolate mofetil were 74% and 71% respectively. This prior opinion will now be taken in to account and will be modified to formulate a Bayesian posterior opinion when data from 40 patients completing the trial randomised at a 1:1 ratio to either receive cyclophosphamide or mycophenolate mofetil are available.

Conclusion
==========

We suggest that this methodological template could be applied to trial design for other rare diseases, and is of particular relevance to rare autoimmune conditions that currently lack a good evidence base for treatment.
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